Trial: 201905131

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

Phase

II (Cancer Control)

Principal Investigator

Van Tine, Brian

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov